Zacks upgraded Coherus Oncology (CHRS) to a Rank #2 (Buy), signaling growing optimism about the company’s earnings prospects. The upgrade could support near-term upside in the stock, likely prompting a modest 1–3% share reaction as investors recalibrate expectations around earnings.
Zacks upgraded Coherus Oncology (CHRS) to a Rank #2 (Buy), signaling growing optimism about the company’s earnings prospects. The upgrade could support near-term upside in the stock, likely prompting a modest 1–3% share reaction as investors recalibrate expectations around earnings.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request a DemoOverall Sentiment
mildly positive
Sentiment Score
0.30
Ticker Sentiment
